
BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100
First-in-Human Trial to Enroll 24 Patients with Refractory Solid Tumors
MOUNTAIN VIEW, Calif., Dec. 21, 2020 /PRNewswire/ — BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for dev… […]